I'm sure it's a piece of it, I'd say it's the Leerink one dollar less PT (on weaker than expected glatopa sales) + the general biotech weakness that is mainly pushing it down today. Biotech investors don't think that far ahead :P
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.